Royalty Pharma (FRA:RPD) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


FRA:RPD Royalty Pharma PLC FRA:RPD
68 GF Score
Price €48.66
GF Value €32.74
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Tariff Resilience Score?

Royalty Pharma FRA:RPD +1.81% 68 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates FRA:RPD with a GF Score™ of 68/100 and a GF Value™ of €32.74 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,374 Biotechnology companies, Royalty Pharma ranks better than 90.39% on this metric.

Royalty Pharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Royalty Pharma has Pharmaceutical royalties less affected by tariffs. However, some exposure exists through international drug manufacturing and distribution networks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Royalty Pharma might have Highly Resilient.

Royalty Pharma  (FRA:RPD) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Royalty Pharma Tariff Resilience Score Related Terms

FRA:RPD vs ROIV, MRNA, BNTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Royalty Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Royalty Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Tariff Resilience Score falls into.


FRA:RPD
68GF Score
Royalty Pharma PLC FRA:RPD
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Royalty Pharma (FRA:RPD) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Royalty Pharma ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Royalty Pharma's Tariff Resilience Score too high?
Royalty Pharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Royalty Pharma's value of 7 is 75% above this industry median. Based on the distribution chart, Royalty Pharma ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Tariff Resilience Score compare to ROIV and MRNA?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #132 out of 1374 companies for Tariff Resilience Score. This places Royalty Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Royalty Pharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.74, compared to a current price of €48.66 — trading 48.6% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Royalty Pharma's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €48.66 is trading 48.6% above its estimated GF Value™ of €32.74. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Tariff Resilience Score: 7
  • GF Value™: €32.74 vs. price of €48.66 (48.6% above fair value)
  • GF Score™: 68/100 with 10 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
68GF Score

Get the complete analysis for FRA:RPD

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.66
Price
€32.74
GF Value